MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair (sotatercept), in newly diagnosed intermediate or high-risk PAH patients, met its primary endpoint. The HYPERION study evaluated Winrevair versus placebo in recently diagnosed adult patients with PAH, WHO Group 1 functional class (FC) II or III at intermediate or high risk of disease progression. The study’s primary...